The use of ursodeoxycholic acid for intrahepatic cholestasis of pregnancy does not reduce adverse perinatal outcomes and should be reconsidered, UK researchers say.

The pregnancy liver disorder is associated with increased rates of stillbirth, preterm birth and admission to the neonatal unit.

Researchers from Kings College, London conducted a randomised controlled trial in 605 women with intrahepatic cholestasis at 33 hospital maternity units in England and Wales.

Participants were randomised to ursodeoxycholic acid (500mg twice daily) or placebo, with the daily dose being gradually adjustable between 500mg and 2g at the treating doctor’s discretion.